BioSpace News Archive

Allogene Therapeutics, Inc. will host a Research & Development Showcase to provide a comprehensive overview of its CD19 and BCMA programs on November 29, 2022.

Mentice has received a 3 million SEK grant from the Swedish government agency for innovation, Vinnova, to improve realism in Mentice virtual reality software environment with a focus on synthetic image generation.

With the amount of information on the internet increasing by the minute, retrieving data from it is like trying to find a needle in a haystack.

Citius Pharmaceuticals, Inc. have been accepted for presentations at the prestigious 64th American Society of Hematology (ASH) Annual Meeting, to be held in New Orleans, December 10-13, 2022.

Altamira Therapeutics Ltd., a company dedicated to developing therapeutics that address important unmet medical needs announced that it has regained compliance with the Nasdaq listing requirements.

Bridge to Life, Ltd. (“Bridge to Life” or the “Company”), a leading global supplier of organ preservation solutions and organ perfusion technologies, announced early results from its multicenter, randomized, controlled Bridge to HOPE Liver Clinical Trial (NCT05045794).

Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2022.

Brand Institute is proud to announce its work with CMP Pharma in developing the brand name TADLIQ®, for tadalafil oral suspension, which was approved by the FDA on June 17, 2022.

Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, will present at the SITC 37th Annual Meeting (2022) in Boston, MA.

Athersys, Inc. announced the pricing of its previously announced “best efforts” public offering of 5,004,545 shares of common stock and warrants to purchase 10,009,090 shares of common stock at a combined price of $1.10 per share and accompanying warrant for aggregate gross proceeds of approximately $5.5 million, before deducting placement agent fees and other offering expenses.